Aminopeptidase N as a potential drug target

[1] Wachmuth ED, Fritze I, Pfleiderer G. An Aminopeptidase Occurring in Pig Kidney. I. An Improved Method of Preparation. Physical and Enzymic Properties. Biochemistry 1966;5:169–174. WachmuthED FritzeI PfleidererG An Aminopeptidase Occurring in Pig Kidney. I. An Improved Method of Preparation. Physical and Enzymic Properties Biochemistry 1966 5 169 174 Search in Google Scholar

[2] DiNardo CD, Cortes JE. Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia. Expert Opin. Investig. Drugs 2013;23:265–272. DiNardoCD CortesJE Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia Expert Opin. Investig. Drugs 2013 23 265 272 Search in Google Scholar

[3] Li Z, Tomlinson ACA, Wong AHM, Zhou D, Desforges M, Talbot PJ, Benlekbir S, Rubinstein JL, Rini JM. The human coronavirus HCoV-229E S-protein structure and receptor binding. eLife 2019;8:art. no. e51230. LiZ TomlinsonACA WongAHM ZhouD DesforgesM TalbotPJ BenlekbirS RubinsteinJL RiniJM The human coronavirus HCoV-229E S-protein structure and receptor binding eLife 2019 8 art. no. e51230. Search in Google Scholar

[4] Ichinose Y, Genka K, Koike T et al. Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J. Natl. Cancer. Inst. 2003;95: 605–610. IchinoseY GenkaK KoikeT Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma J. Natl. Cancer. Inst. 2003 95 605 610 Search in Google Scholar

[5] Lee S, Desai P, Edirisinghe B, Pianello S et al. Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy. Leuk Lymphoma. 2021;62:498–500. LeeS DesaiP EdirisingheB PianelloS Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy Leuk Lymphoma 2021 62 498 500 Search in Google Scholar

[6] Dennis M, Burnett A, Hills R et al. National Cancer Research Institute (NCRI) acute myeloid leukemia (AML) Working Group. A randomized evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukemia: results of the LI-1 trial. Br. J. Haematol. 2021;194:298–308. DennisM BurnettA HillsR National Cancer Research Institute (NCRI) acute myeloid leukemia (AML) Working Group A randomized evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukemia: results of the LI-1 trial Br. J. Haematol. 2021 194 298 308 Search in Google Scholar

[7] Reid AH, Protheroe A, Attard G, Hayward N et al. A first-in-man phase I and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. Clin. Cancer. Res. 2009;15:4978–4985. ReidAH ProtheroeA AttardG HaywardN A first-in-man phase I and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors Clin. Cancer. Res. 2009 15 4978 4985 Search in Google Scholar

[8] Farsa O, Dockal M, Kovacikova J, Benesova, M. Synthesis of 2-{[2-(2-oxo-1-azacycloalkyl)acetamido]phenoxy}acetic acids and their activity as aminopeptidase M inhibitors. J. Serb. Chem. Soc. 2008;73:771–780. FarsaO DockalM KovacikovaJ BenesovaM Synthesis of 2-{[2-(2-oxo-1-azacycloalkyl)acetamido]phenoxy}acetic acids and their activity as aminopeptidase M inhibitors J. Serb. Chem. Soc. 2008 73 771 780 Search in Google Scholar

[9] Farsa O, Sedlakova S, Podlipna J, Maxa J. Aminopeptidase N inhibition could be involved in the anti-angiogenic effect of dobesilates. J. Serb. Chem. Soc. 2014;79:605–612. FarsaO SedlakovaS PodlipnaJ MaxaJ Aminopeptidase N inhibition could be involved in the anti-angiogenic effect of dobesilates J. Serb. Chem. Soc. 2014 79 605 612 Search in Google Scholar

[10] Farsa O, Kana J, Macku I et al. Synthesis and aminopeptidase N inhibiting activity of 2-(nitrophenoxymethyl)-[1,3,2] dioxaborolan-2-ols and their open analogs. Acta Pol. Pharm. 2017;74:127–135. FarsaO KanaJ MackuI Synthesis and aminopeptidase N inhibiting activity of 2-(nitrophenoxymethyl)-[1,3,2] dioxaborolan-2-ols and their open analogs Acta Pol. Pharm. 2017 74 127 135 Search in Google Scholar

[11] Farsa O, Haluska M. A single-and multiparametric QSAR study of aminopeptidase N inhibitors. Farmacia 2016;64:283–290. FarsaO HaluskaM A single-and multiparametric QSAR study of aminopeptidase N inhibitors Farmacia 2016 64 283 290 Search in Google Scholar

[12] Amin SA, Adhikari N, Jha T. Design of Aminopeptidase N Inhibitors as Anti-cancer Agents. J. Med. Chem. 2018;61:6468–6490. AminSA AdhikariN JhaT Design of Aminopeptidase N Inhibitors as Anti-cancer Agents J. Med. Chem. 2018 61 6468 6490 Search in Google Scholar

[13] Farsa O, Ballayová V, Žáčková R, Kollar P, Kauerová T, Zubáč P. Aminopeptidase N Inhibitors as Pointers for Overcoming Antitumor Treatment Resistance. Int. J. Mol. Sci. 2022;23:9813. FarsaO BallayováV ŽáčkováR KollarP KauerováT ZubáčP Aminopeptidase N Inhibitors as Pointers for Overcoming Antitumor Treatment Resistance Int. J. Mol. Sci. 2022 23 9813 Search in Google Scholar